Sodium iodide
As of the edition of 20 October 2026, Sodium iodide is a small molecule: marketed, first approved in 1982 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1999
- Kind
- Small molecule
- Brand name
- Iodotope
- First approved
- 1 January 1982 (US)
- Approvals on record
- 23 in 2 regions
- Holder of the most recent approval
- Jubilant DraxImage; 8 holders in all
- Registered trials
- 5, 1 stopped early
- Disease areas
- Heart and blood vessels; Cancer; Hormones; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 1 | 0 | 1 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 5 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Draximage | Later holder | 2003 to now |
| Bracco Diagnostics | Acquired holder | 2003 to now |
| Cis Bioindustries Compagnie | Acquired holder | 2003 to now |
| Cardinal Health 418 | Acquired holder | 2015 to now |
| Curium | Acquired holder | 2019 to now |
| Jubilant DraxImage | Acquired holder | 2020 to now |
| SUN Pharmaceutical Industries | Acquired holder | 2025 to now |
| Bristol Myers Squibb | Earlier holder | |
| Byk-Mallinckrodt CIL | Later holder | |
| GE Healthcare | Later holder |